Empfehlungen für das Management der ankylosierenden Spondylitis

Zusammenfassung

Auf Initiative von ASAS (Assessment of SpondyloArthritis International Society) und EULAR (European League against Rheumatism) sind zehn evidenzbasierte Empfehlungen für das Management der ankylosierenden Spondylitis (AS) erstellt worden. Entsprechend dieser internationalen Empfehlung soll sich das Management der AS an der Krankheitsmanifestation, der Schwere der Erkrankung und mehreren anderen Faktoren (z. B. Patientenwünsche und -erwartungen) orientieren. Die ersten drei der zehn Schlüsselempfehlungen stellen die generelle Konzeption für das Management der AS dar, während die übrigen sieben spezifische Behandlungsmodalitäten der Erkrankung beschreiben. Die Empfehlung ist mit breiter Zustimmung in Europa evaluiert worden. Basierend auf dieser internationalen Empfehlung ist im deutschsprachigen Raum eine Expertenversion adaptiert und ebenfalls mit breiter Zustimmung evaluiert worden. Die internationale Empfehlung für das Management der AS zielt auf die Bedürfnisse von Angehörigen der Gesundheitsberufe ab und ist in der Regel für ASPatienten nicht verständlich. Daher ist in Kooperation von ASAS und EULAR eine für Patienten verständliche Version der Empfehlungen erarbeitet worden.

Summary

Ten key recommendations for the management of ankylosing spondylitis (AS) have been developed in cooperation with ASAS (Assessment of SpondyloArthritis International Society) und EULAR (European League against Rheumatism). The management of AS should be tailored according to the current manifestations of the disease, the disease severity and other factors like wishes and expectations of the patients. The first three recommendations deal with general concepts in the management of AS, and the remaining seven describe specific treatments in use for AS. The recommendations have already been evaluated with a marked consensus in different European countries. Based on this version a German health professional version has been adapted and evaluate in the German language area. The ASAS/EULAR recommendations for the management of AS have been developed for a target population of health professionals and could not be understood by most of the patients with AS. Thus, the health professional version was translated into a language that can be understood by AS patients.

Schlüsselwörter

Management der ankylosierenden Spondylitis - Empfehlungen

Keywords

Management of ankylosing spondylitis - recommendations

• References

• 1 Amor B, Santos RS, Nahal R. et al. Predicitve factors for the longterm outcome of spondyloarthropathies. J Rheumatol 1994; 21: 1883-1887.
• 2 Braun J, Baraliakos X, Brandt J, Sieper J. Therapy of ankylosing spondylitis – a review. Part II: Biological therapies in the spondyloarthritides. Scand J Rheumatol 2005; 34: 178-190.
• 3 Braun J, Baraliakos X, Godolias G, Böhm H. Therapy of ankylosing spondylitis – a review. Part I: Conventional medical treatment and surgical therapy. Scand J Rheumatol 2005; 34: 97-108.
• 4 Braun J, Davis J, Dougados M. et al. for the ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondyli-tis. Ann Rheum Dis 2006; 65: 316-320.
• 5 Braun J, Pharm T, Sieper J. et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with anky-losing spondylitis. Ann Rheum Dis 2003; 62: 817-824.
• 6 Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369: 1379-1390.
• 7 Braun J, Zochling J, Märker-Hermann E. et al. Empfehlungen für das Management der ankylosierenden Spondylitis gemäß ASAS/EULAR. Z Rheumatol 2006; 65: 728-742.
• 8 Braun J, Zochling J, Märker-Hermann E. et al. Recommendations for the management of ankylo-sing spondylitis after ASAS/EULAR. Evaluation in the German language area. Z Rheumatol 2006; 65: 728-742.
• 9 Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008; 23: CD002822
• 10 Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 2002; 325: 619-623.
• 11 Gossec L, Dougados M, Phillips C. et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of Ankylo-sing Spondylitis: results of a study among 1,507 rheumatologists. Ann Rheum Dis 2007; 67: 782-788.
• 12 Grimshaw JM, Thomas RE, MacLennan G. et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004; 8 iii-iv 1-72.
• 13 Kiltz U, van der Heijde D, Mielants H. et al. on behalf of the PARE/EULAR patient initiative group. ASAS/EULAR recommendations for the management of ankylosing spondylitis – the patient version. Ann Rheum Dis (submitted).
• 14 Kirwan J, Edwards A, Huitfeldt B. et al. The course of established ankylosing spondylitis and the effects of sulphasalzine over 3 years. Br J Rheumatol 1993; 32: 729-733.
• 15 Maugars Y, Mathis C, Vilon P, Prost A. Corticosteroid injection of the sacroiliac joint in patients with seronegative spondyloarthropathy. Arthritis Rheum 1992; 35: 564-568.
• 16 Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63: 17-32.
• 17 Simon JA, Burgos-Vargas R. Agreement of Mexi-can rheumatologists with the A Sessment in Anky-losing Spondylitis International Working Group and the European League Against Rheumatism recommendations for the management of ankylo-sing spondylitis. Ann Rheum Dis 2006; 65: 1535-1536.
• 18 Van der Heijde D, Bellamy N, Calin N. et al. on behalf of the Assessment in Ankylosing Spondylitis Working Group. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997; 24: 2225-2229.
• 19 Wanders A, van der Heijde D, Landewe R. et al. Nonsteroidal Antiinflammatory Drugs Reduce Radiographic Progression in Patients with Anky-losing Spondylitis. A Randomized Clinical Trial. Arthritis Rheum 2005; 52 (06) 1756-1765.
• 20 Zochling J, van der Heijde D, Burgos-Vargas R. et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-452.
• 21 Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of anky-losing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65: 423-432.